IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
Zeposia Adds A Second Oral Advanced Therapy
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
You may also be interested in...
First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
Morphic Shows Potential For An ‘Oral Entyvio’ With Phase IIa Data
MORF-057, addressing the same target as Takeda blockbuster Entyvio, shows efficacy and safety in ulcerative colitis. Various companies have sought an oral competitor to established biologics in UC.
Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis
The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.